Crosspoint Capital Strategies’s Pfizer PFE Stock Holding History

Crosspoint Capital Strategies’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-75	Closed	-$4K	–	21
2022 Q1	$4K	Buy	+75	New	+$3.89K	0.01%	34
2016 Q1	–	Sell	-23,246	Closed	-$689K	–	614
2015 Q4	$689K	Sell	23,246 -976	-4%	-$30.7K	0.18%	128
2015 Q3	$722K	Sell	24,222 -16,817	-41%	-$539K	0.84%	27
2015 Q2	$1.31M	Sell	41,039 -1,805	-4%	-$58.8K	0.37%	54
2015 Q1	$1.41M	Sell	42,844 -5,735	-12%	-$182K	0.68%	43
2014 Q4	$1.44M	Buy	48,579 +22,577	+87%	+$647K	0.5%	55
2014 Q3	$729K	Sell	26,002 -7,914	-23%	-$222K	0.54%	57
2014 Q2	$969K	Sell	33,916 -2,309	-6%	-$65.8K	0.37%	70
2014 Q1	$1.1M	Buy	36,225 +318	+0.9%	+$9.48K	0.45%	51
2013 Q4	$1.11M	Buy	+35,907	New	+$1.05M	0.37%	58

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Crosspoint Capital Strategies's PFE Position: Q2 2022 in Review

Crosspoint Capital Strategies sold out of Pfizer (PFE) in Q2 2022, closing a stake of 75 shares — an estimated $4K sold.

Crosspoint Capital Strategies first reported a position in PFE in Q4 2013 and held it in 10 quarters. The position peaked at $1.44M in Q4 2014. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

Crosspoint Capital Strategies reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
Crosspoint Capital Strategies sold 75 Pfizer shares in Q2 2022, an estimated $4K.
Crosspoint Capital Strategies first reported a position in Pfizer in Q4 2013 and held it in 10 quarters.
Crosspoint Capital Strategies's Pfizer position peaked at $1.44M in Q4 2014.
3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2022, filed 12 Aug 2022.